Vantage Investment Advisors’s GSK GSK Stock Holding History

Vantage Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$11K	Hold	331	–	–	﹤0.01%	516
2018 Q2	$17K	Hold	331	–	–	﹤0.01%	449
2018 Q1	$16K	Sell	331 -200	-38%	-$9.31K	﹤0.01%	465
2017 Q4	$15K	Buy	531 +19	+4%	+$878	﹤0.01%	494
2017 Q3	$26K	Hold	512	–	–	0.01%	388
2017 Q2	$28K	Sell	512 -120	-19%	-$6.4K	0.01%	366
2017 Q1	$33K	Hold	632	–	–	0.01%	317
2016 Q4	$30K	Hold	632	–	–	0.01%	333
2016 Q3	$34K	Sell	632 -382	-38%	-$20.9K	0.02%	296
2016 Q2	$55K	Buy	1,014 +221	+28%	+$11.6K	0.02%	247
2016 Q1	$40K	Buy	793 +360	+83%	+$17.9K	0.02%	275
2015 Q4	$22K	Hold	433	–	–	0.01%	368
2015 Q3	$21K	Hold	433	–	–	0.01%	361
2015 Q2	$23K	Sell	433 -433	-50%	-$24.4K	0.01%	358
2015 Q1	$50K	Buy	866 +433	+100%	+$24.8K	0.01%	340
2014 Q4	$23K	Hold	433	–	–	0.01%	350
2014 Q3	$25K	Hold	433	–	–	0.02%	317
2014 Q2	$29K	Hold	433	–	–	0.02%	312
2014 Q1	$29K	Hold	433	–	–	0.02%	284
2013 Q4	$29K	Buy	+433	New	+$28.1K	0.02%	271

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vantage Investment Advisors's GSK Position: Q3 2018 in Review

Vantage Investment Advisors held its GSK (GSK) position steady in Q3 2018 at 331 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #516.

Vantage Investment Advisors first reported a position in GSK in Q4 2013 and has held it in 20 quarters since. The position peaked at $55K in Q2 2016. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

Vantage Investment Advisors held 331 shares of GSK worth $11K as of Q3 2018.
Vantage Investment Advisors left its GSK share count unchanged in Q3 2018.
GSK made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #516 holding.
Vantage Investment Advisors first reported a position in GSK in Q4 2013 and has held it in 20 quarters since.
Vantage Investment Advisors's GSK position peaked at $55K in Q2 2016.
787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.